Presentation - Reducing Progression Rate of Age-Related Macular Degeneration
ASX Announcement General AlphaRET
21 Dec, 2021
Cancel - Proposed Issue of Securities
ASX Announcement General
30 Nov, 2021
Notification of Issue of Securities 2
ASX Announcement General
30 Nov, 2021
Notification of Issue of Securities
ASX Announcement General
30 Nov, 2021
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
ASX Announcement General
30 Nov, 2021
Appendix 3Z Final Director's Interest Notice
ASX Announcement General
25 Nov, 2021
2021 Annual General Meeting Voting Results
ASX Announcement General
25 Nov, 2021
Presentation - Annual General Meeting 2021
ASX Announcement General
24 Nov, 2021
Withdrawal of AGM Resolutions 2,4,6,7,8 and 9 From Notice of Meeting
ASX Announcement General
24 Nov, 2021
Resignation of Mr Alex Sundich
ASX Announcement General
24 Nov, 2021
Jobkeeper Payments Notification
ASX Announcement General
11 Nov, 2021
Clarification of Escrow Details
ASX Announcement General
5 Nov, 2021
US Government Stimulus Loan Forgiven
ASX Announcement General
26 Oct, 2021
Notice of Annual General Meeting
ASX Announcement General
21 Oct, 2021
5-Year Efficacy and Safety of iTrack™ to be Spotlighted at ESCRS 2021
ASX Announcement General iTrack Molteno3 AlphaRET
7 Oct, 2021
EYE FY21 Date of AGM & Closing Date for Director Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
30 Sep, 2021
Nova Eye Medical to Present at ASX Small to Mid-Cap Conference
ASX Announcement General iTrack Molteno3 AlphaRET
10 Sep, 2021
Closure of Share Sale Facility for Unmarketable Parcels
ASX Announcement General
3 Sep, 2021
Proposed issue of securities
ASX Announcement General
26 Aug, 2021
Nova Eye Medical Acquires Key Glaucoma Patents to Drive New Product Expansion
ASX Announcement General iTrack
26 Aug, 2021
Nova Eye Medical Reports 25% Growth in Glaucoma Device Sales for the 2021 Fiscal Year
ASX Announcement General
19 Aug, 2021
Appendix 4E
ASX Announcement General
19 Aug, 2021
Appendix 4G & Corporate Governance Statement
ASX Announcement General
19 Aug, 2021
Application for Quotation of Securities
ASX Announcement General
18 Aug, 2021
Proposed Issue of Securities
ASX Announcement General
18 Aug, 2021
Notice of Upcoming Investor Call – Full Year (FY21) Results
ASX Announcement General
11 Aug, 2021
Notice of change of interests of substantial holder
ASX Announcement General
29 Jul, 2021
Nova Eye Medical FY21 Trading Update
ASX Announcement General
20 Jul, 2021
NOTICE OF SHARE SALE FACILITY FOR HOLDERS OF LESS THAN MARKETABLE PARCELS
ASX Announcement General
15 Jul, 2021
Nova Eye Establishes Share Sale Facility for Unmarketable Parcels
ASX Announcement General
15 Jul, 2021
Nova Eye Medical Files IDE Application with the FDA to Commence a Pivotal Study in the US Evaluating 2RT
ASX Announcement AlphaRET
5 Jul, 2021
2RT® Featured at the 2021 Meeting of the Association for Research in Vision and Ophthalmology
ASX Announcement General AlphaRET
3 May, 2021
Notice of Change of Interests of Substantial Holder
ASX Announcement General
30 Apr, 2021
First Patient Enrolled in MAGIC Clinical Trial for Glaucoma
ASX Announcement General iTrack
30 Apr, 2021
Five-Year Post-LEAD Review Shows Improvement in 2RT® Treatment Benefits for iAMD
ASX Announcement General AlphaRET
5 Mar, 2021
Clinical Trial to Assess Efficacy and Safety of iTrack™ in the Treatment of Mild to Moderate Glaucoma
ASX Announcement General iTrack
2 Mar, 2021
First Half FY2021 Accounts
ASX Announcement General
25 Feb, 2021
1HFY21: Growth in Glaucoma Surgical Devices Segment Despite Pandemic
ASX Announcement General
25 Feb, 2021
Notice of Upcoming Investor Call – First Half FY21 Results
ASX Announcement General
18 Feb, 2021
For investor enquires please contact:
Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More